Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824767 · ClinicalTrials.gov registry record · Phase 4
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
A Phase 4 study of Septic Shock and Vasodilatory Shock, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05824767: Completed Phase 4 study of Septic Shock and Vasodilatory Shock, sponsored by University of New Mexi.
NCT05824767 is a Phase 4 study of Septic Shock and Vasodilatory Shock that has completed, run by University of New Mexi. The registered enrollment target is 40 participants, below the 5,057-participant average among 24 other Septic Shock trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05824767, a Phase 4 study of Septic Shock and Vasodilatory Shock, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded study.
Primary Outcome
BP response will be assessed at 3 hours in both groups and measured using NED. The primary outcome will be ability of baseline renin (obtained at drug initiation or equivalent SOC timepoint) to predict total NED at 3 hours, stratified by treatment arm (AngII vs. SOC) and adjusted for baseline Sequential Organ Failure Assessment (SOFA) scores. Shown are beta-coefficients from linear regression analyses between baseline levels of each biomarker and change in NED at 3 hours, adjusted for baseline S
Conditions Studied
Interventions
- DRUG Angiotensin II
Study Locations (1)
New Mexico
- University of New Mexico Health Sciences Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2025-03-12 |
| Phase | Phase 4 |
What the finished NCT05824767 record still lists
NCT05824767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 5,057-participant average among 24 other Septic Shock trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Septic Shock appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II is the first listed.
NCT05824767 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT05824767 about?
NCT05824767 is a clinical study titled "Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock". This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomark...
What is the current status of trial NCT05824767?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-04-17. Estimated completion is 2025-03-12.
What conditions does trial NCT05824767 study?
This clinical trial studies the following conditions: Septic Shock, Vasodilatory Shock.
What interventions are being tested in trial NCT05824767?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT05824767?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05824767 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05824767's enrollment target sits among peer trials
40 19th of 24 higher than 6 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Early Angiotensin II in the Emergency Department
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Vasopressin for Septic Shock Pragmatic Trial
ACTIVE NOT RECRUITING · Phase 4
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI